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Abstract
Introduction 3′-deoxy-3′-[18F]fluorothymidine (18F–FLT) positron emission tomography (PET) provides a non-invasive
method to assess cellular proliferation and response to antitumor therapy. Quantitative 18F–FLT uptake metrics are being
used for evaluation of proliferative response in investigational setting, however multi-center repeatability needs to be
established. The aim of this study was to determine the repeatability of 18F–FLT tumor uptake metrics by re-analyzing
individual patient data from previously published reports using the same tumor segmentation method and repeatability
metrics across cohorts.
Methods A systematic search in PubMed, EMBASE.com and the Cochrane Library from inception-October 2016
yielded five 18F–FLT repeatability cohorts in solid tumors. 18F–FLT avid lesions were delineated using a 50% isocontour
adapted for local background on test and retest scans. SUVmax, SUVmean, SUVpeak, proliferative volume and total lesion
uptake (TLU) were calculated. Repeatability was assessed using the repeatability coefficient (RC = 1.96 × SD of test–
retest differences), linear regression analysis, and the intra-class correlation coefficient (ICC). The impact of different
lesion selection criteria was also evaluated.
Results Images from four cohorts containing 30 patients with 52 lesions were obtained and analyzed (ten in breast
cancer, nine in head and neck squamous cell carcinoma, and 33 in non-small cell lung cancer patients). A good
correlation was found between test–retest data for all 18F–FLT uptake metrics (R2 ≥ 0.93; ICC ≥ 0.96). Best repeatability
was found for SUVpeak (RC: 23.1%), without significant differences in RC between different SUV metrics.
Repeatability of proliferative volume (RC: 36.0%) and TLU (RC: 36.4%) was worse than SUV. Lesion selection
methods based on SUVmax ≥ 4.0 improved the repeatability of volumetric metrics (RC: 26–28%), but did not affect
the repeatability of SUV metrics.
Conclusions In multi-center studies, differences ≥ 25% in 18F–FLT SUV metrics likely represent a true change in tumor uptake.
Larger differences are required for FLT metrics comprising volume estimates when no lesion selection criteria are applied.
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Introduction
Despite the recent progress made in cancer diagnosis and
treatment, cancer remains the number one cause of death in
the Western world [1]. Although treatment can be very effec-
tive, most regimens fail for a substantial number of patients.
Early response evaluation enables the treating physician to
differentiate responders from non-responders, to stop the treat-
ment in the non-responder cohort timely and reliably. This
potentially helps to limit side effects of anticancer therapies
and avoid treatment delay of subsequent lines, thereby reduc-
ing patient burden and healthcare costs.
Several imaging modalities can be used to non-invasively
assess response to treatment. Most modalities only evaluate
morphological features, yet slow changes in tumor morphol-
ogy or even pseudoprogression, as can be seen in case of
immunotherapy, impair the use of morphological features in
early repsonse assessment [2, 3]. However, morphological
changes are often preceded by changes in tumor metabolism
[4]. These early functional changes can be assessed using
molecular imaging techniques such as PET, which may allow
for more accurate early response evaluation.
There are several different radiotracers available to assess a
variety of metabolic processes. One of these tracers is 3′-de-
oxy-3′-[18F]fluorothymidine (18F–FLT) and provides a meth-
od to evaluate cellular proliferation. Proliferation is a central
hallmark of tumor growth and previous studies have validated
18F–FLT against the immunohistochemistry proliferation
marker Ki67 in pathological specimens for several tumor
types [5–7]. Unfortunately, 18F–FLT PET did not improve
tumor detection or staging compared to 2-deoxy-
2-[18F]fluoro-D-glucose (18F–FDG) due to lower sensitivity
[8]. As proliferation is more cancer-specific compared to gly-
colysis, 18F–FLT PET has potential as an imaging biomarker
for response assessment.
Cytotoxic and cytostatic therapies aim, respectively, to
kill tumor cells (mainly highly proliferating cells) and
diminish tumor growth, both leading to a decrease in cel-
lular proliferation. After initiation of any antitumor treat-
ment, this change in proliferation can be evaluated using
18F–FLT PET/CT. Several studies have been performed
investigating 18F–FLT PET/CT as quantitative imaging
biomarker of response [9], nevertheless most did not take
variability into account.
For 18F–FDG, the repeatability of quantitative uptake mea-
sures has beenwidely investigated [10–13] and integrated into
the response assessment criteria PERCIST [2]. Up to now,
repeatability of quantitative 18F–FLT PET/CT has only been
studied in a few small single-center cohorts (≤ 10 patients)
[14–17]. Moreover, there was variability in uptake intervals,
tumor delineation methods, and image analyses. The aim of
this study was therefore to perform an individual patient data
meta-analyses by re-analyzing all available 18F–FLT
repeatability data from previously published studies and to
determine the repeatability of several quantitative 18F–FLT
tumor uptake metrics using similar uptake intervals, the same
tumor segmentation method, and the same repeatability met-
rics as would be done in a prospective multi-center study.
Methods
Search strategy and selection process
To identify all relevant publications, a systemic search was
performed in PubMed, EMBASE.com and the Cochrane
Library (via Wiley) from inception to October 20, 2016 (last
elicitation). A combination of the search terms comprising
‘FLT-PET’ and ‘neoplasms’ was used. This included MeSH
terms and controlled terms from EMtree for PubMed and
EMBASE.com, respectively, as well as free-text terms. We
only used free-text terms in the Cochrane Library (see supple-
mental data). All potentially relevant titles and abstracts were
screened for eligibility. Full-text articles were checked for el-
igibility criteria where necessary. References of eligible pub-
lications were checked for relevant publications. We have also
checked ClinicalTrials.gov and The European Union Clinical
Trials Register for ongoing and unpublished studies.
Studies were included if they met the following criteria:
– The study investigated the repeatability of 18F–FLT PET
or PET/CT in oncological patients;
– Scans were performed on two separate days using the
same scanner; and
– Patients were not treated in between both scans.
Studies were excluded if they met the following criteria:
– Animal or in vitro studies;
– Focused on tumors of the central nervous system (to
avoid differences in pharmacokinetics due to the blood–
brain barrier);
– Not available in full text or not written in English; and
– Reviews, editorials, letters, legal cases, interviews, case
reports, and comments.
Data analysis
Sites from all identified cohorts were contacted, and per-
mission was requested to re-analyze the original 18F–FLT
PET repeatability scans. All datasets consisted of 60- or
95-min dynamic test and retest 18F–FLT PET scans.
Where permission was granted, original 18F–FLT scans
of all individual patients were supplied in DICOM or
Analyze format. Prior to re-analysis, all scans were
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checked for technical issues and artifacts. If any technical
issues or artifacts were present, data were cross-checked
with the original research teams. After checking of the
scan data, static standard uptake value (SUV) images
were generated from the dynamic images: 40–65 or 45–
60 min post-injection, depending on the original frame
definition. A 5-mm Gaussian filter was applied to the
non-smoothed reconstructed images to match the spatial
resolution between existing datasets and with previously
published data. New volumes of interest (VOI) were de-
fined by segmenting tumors using a 50% isocontour of
the SUVpeak (1.2 cm in diameter sphere positioned to
maximize its mean value), adapted for local background
(in-house developed software) [12, 18]. For each VOI,
SUVmax, SUVmean, SUVpeak, proliferative volume (50%
threshold of SUVpeak corrected for local background)
and total lesion uptake (TLU, product of SUVmean and
proliferative volume) was determined. These quantitative
18F–FLT uptake metrics were checked for outliers and
discrepancies with the original data, however no impor-
tant issues were identified. In addition, tumor-to-blood
ratios (TBR) were calculated by normalizing tumor
SUVs to the bloodpool SUVmean of a large vascular struc-
ture (2 × 2 voxel VOI in five consecutive planes) [19].
18F–FLT uptake in the tumor was normalized to the
SUVmean of the carotid artery in HNC data and to the
ascending aorta for all other lesions. All SUVs were cal-
culated by normalizing the radioactivity concentrations by
the injected 18F–FLT dose and body weight and were
corrected for physical decay.
Statistical analysis
Repeatability of the quantitative uptake and volume met-
rics was determined by calculating the mean and stan-
dard deviation (SD) of the percentage differences be-
tween the two baseline scans:
%Difference ¼ Scan 2−Scan 1
Scan 1þ Scan 2ð Þ=2  100 ð1Þ
Normality of the data was assessed using histogram
analyses and quantile-quantile plots (data not shown).
The repeatability coefficients (RC) were calculated as
1.96 × SD of the percentage differences. A paired t test
was performed to test for significant differences in mean
uptake between both baseline scans. To assess the signifi-
cance of differences in RC, the Levene’s test was used.
Moreover, the intra-class correlation coefficient (ICC)
using a two-way mixed model, model II regression analy-
sis [20] and Bland–Altman plots were used to evaluate
correlations and biases between the test-and-retest scans.
The effect of various lesion selection strategies on
repeatability was evaluated: lesions ≥ 4.2 ml (diameter ≥
20 mm) [18], SUVmax ≥ 4.0 [10, 11], hottest lesion per scan
(highest SUVmax) or primary lesions only. In addition, the
uptake values of individual lesions were averaged per pa-
tient to obtain the averaged uptake and assess repeatability
on a patient level. All statistical analyses were performed
using SPSS 22.0 (SPSS, Chicago, IL, USA).
Results
Search results
The literature search generated 1728 results: 630 in
PubMed, 1076 in EMBASE.com and 22 in the Cochrane
Library. No ongoing or unpublished trials were identified.
After removing duplicates, 1172 references remained
(Fig. 1). Out of 1172, four articles (five patient cohorts)
were considered eligible [14–17]. We obtained permission
to re-analyze the original 18F–FLT repeatability data from
four of these cohorts, comprising data of 30 patients and
52 individual lesions (ten in breast cancer [14], nine in
head and neck squamous cell carcinoma [15], and 33 in
non-small cell lung cancer patients from two cohorts [15,
16]; Fig. 2). All patients were included in this individual
patient data meta-analysis and no scans had to be exclud-
ed. An overview of the cohorts can be found in Table 1.
Repeatability
SUV metrics were lower in the lung cancer dataset from
Trigonis et al. [16] compared to the other three datasets
(average SUVmean: 2.4 vs. 3.5, respectively; p < 0.05). In
addition, the SUVmax and SUVpeak values in the breast
cancer dataset from Kenny et al. [14] were higher com-
pared to those from de Langen et al. [15]. Proliferative
volumes and TLU were significantly smaller in the HNC
group and the NSCLC lesions in the dataset from
Trigonis et al. [16] were also significantly smaller than
in the de Langen et al. dataset [15]. Despite overall pro-
liferative volumes of the retest scan being significantly
larger than the test scans (MATV: 14.5 vs. 15.6 ml, p =
0.02), no differences were found between the SUV met-
rics from test-and-retest scans (Table 2). When assessed
per site, a small but significant difference in proliferative
volume and TLU was only found in the dataset from
Trigonis et al. (mean difference −2.3 ml and −4.2 ml
respectively, p < 0.01) [16].
Correlations between test-and-retest scans were strong for
all uptake metrics per lesion as well as averaged per patient
(R2 ≥ 0.93 and ICC ≥ 0.96, Fig. 3). Moreover, no systematic
bias was present between both scans as revealed by the corre-
lation plots (slope, 0.98–1.04, Fig. 3) and the Bland–Altman
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Records screened
(n=1172)
Records excluded:
- Animal or in vitro (n=308)
- Publication type (n=312)
- Not evaluating repeatability  
(n=539)
- Evaluating repeatability in 
brain (n=1)
Full-text articles excluded:
- Not evaluating repeatability 
(n=3)
- Previously described cohort 
(n=5)
repeatability data requested
(n=4 (5 cohorts))
Records identified through database 
searching
(n =1728) 
Records after duplicates removed
(n=1172)
Full-text articles assessed for 
eligibility
(n=12)
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Patient cohorts excluded:
- No permission obtained 
(n=1)
Fig. 1 Flowchart of the search-
and-selection procedure of studies
Fig. 2 18F–FLT PET scan of all
four cohorts. a Kenny et al.
(breast); b Trigonis et al.
(NSCLC); c, d de Langen et al.,
HNC and NSCLC, respectively
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plots (Fig. 3). Overall, the best repeatability of quantitative
18F–FLT PET/CT was obtained using SUVpeak (RCs 23.1%,
Table 3). No differences in RCs were found between the indi-
vidual SUV metrics.
Variability of proliferative volume and TLU (RCs 36.0
and 36.4%, respectively) were significantly worse than for
SUV metrics, with an average increase in RC of 9.6 ± 6.6%
(p ≤ 0.02)(Fig. 4). When the datasets were evaluated indi-
vidually, variability of SUVpeak and SUVmean within the de
Langen et al. [15] cohorts was significantly smaller com-
pared to those of the breast cancer dataset, the only one
reconstructed with FBP (p < 0.02) [14]. In general, the
largest variability was seen in the latter dataset. When com-
paring only the OSEM reconstructed datasets, RCs for
SUVmax, SUVpeak, and SUVmean changed to 25, 20, and
17% respectively, but RCs of proliferative volumes and
TLU remained close to 35%. An overview of the absolute
repeatability coefficients for each quantitative uptake met-
ric can be found in supplemental Tables 4 and 5.
Assessment of repeatability on a patient level improved
repeatability in general (Table 4). Improvement of repeat-
ability weighted for lesions number was < 2% compared
to unweighted averaging per patient. For the SUV met-
rics, a decrease in RC was largest in the de Langen dataset
[15]. Only SUVmean showed a slight increase in variabil-
ity, which was caused by one lesion with a 53% difference
(4 SDs) between both scans from the breast cancer
dataset. If excluded, repeatability of SUVmean improved
to 19%, while other SUV metrics remained unaffected.
RCs of proliferative volume and TLU also decreased to
< 30%, with the exception of the breast dataset [14].
Lesion selection
Assessing repeatability including only lesions with SUVmax ≥
4.0 decreased variability of volumetric metrics but did not
influence RCs of SUV metrics (RCs 26–28%, Fig. 5). The
former is mainly caused by a large decrease of RCs in the
Trigonis dataset (−20%). If only lesions larger than 4.2 ml
were included in the analysis, no significant change in vari-
ability of SUV, proliferative volume or TLU was seen (RCs
22–25% and 34–36%, respectively). Similar results were ob-
served when only the hottest or primary lesions were assessed.
Combining the two selection criteria SUVmax ≥ 4.0 and le-
sions ≥ 4.2 ml did not further improve results. No significant
change in repeatability of SUV metrics was seen when ana-
lyzing cohorts individually. In addition, applying lesions se-
lection criteria to the per-patient analysis did not decrease
variability of SUVand volumetric 18F–FLT uptake measures.
Normalization to blood uptake
Overall, repeatability deteriorated significantly when TBR
was used (RCs +49–52%; p < 0.02). The effect on the HNC
dataset using the carotid artery was not different compared to
the lung cancer datasets using the larger ascending aorta. In
particular, repeatability of the breast dataset worsened by cal-
culating the TBR, showing an increase of > 50% for all met-
rics. This is likely explained by the variability of the
bloodpool SUV being significantly larger in the FBP recon-
structed dataset compared to the OSEM reconstructed datasets
(SD: 34 vs. 13%). When this cohort was excluded, RCs of
Table 1 Cohort and patient characteristics; median (range)
Characteristic Kenny de Langen Trigonis
Cancer type BC NSCLC HNC NSCLC
Patients 8 9 6 7
Tumors 10 15 9 18
Scanner - Manufacturer - Model Siemens ECAT/962 HR+ Siemens ECAT EXACT HR+ Siemens ECAT EXACT HR+ Siemens Biograph 6
Truepoint TrueV
Reconstruction FBP OSEM OSEM OSEM
Iteration – 2 2 4
Subsets – 16 16 21
Voxel size (mm3) 2.62 × 2.62 × 2.42 2.57 × 2.57 × 2.43 3.43 × 3.34 × 2.43 2.67 × 2.67 × 2.00
Static reconstruction - Scan interval
(min) - Frames:
45–65 Averaged 45–60 Averaged 45–60 Averaged 45–60 Summed
Time between scans (days) 4.5 (2–9) 2 (1–6) 1 (1) 4 (2–6)
Weight (kg) - Test - Retest 61.6 (53–106) 61.9
(51.3–107)
71 (61–83) 71
(61–86.5)
77 (65–85) 77 (65–85) 81.5 (66–96.8) 81.4
(65.6–97)
Injected dose (MBq) - Test - Retest 369 (246–380) 312
(153–379)
385 (253–389) 365
(341–397)
375 (334–390) 376
(354–405)
289 (254–332) 328
(283–361)
*No significant differences were present between the test-and-retest scans for any of the studies (Wilcoxon signed-rank test
BC breast cancer, NSCLC non-small cell lung cancer, HNC head and neck cancer
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TBR metrics were no longer significantly different from the
SUV metrics.
Discussion
This individual patient data meta-analysis combined avail-
able data from four different 18F–FLT PET test–retest co-
horts acquired in three different cancer types at three dif-
ferent centers. Of the quantitative 18F–FLT uptake mea-
sures commonly used in oncological setting, SUV metrics
showed better repeatability overall than the volumetric
metrics. Unfortunately, we did not obtain permission from
one study to re-analyze their data [17]. However, individ-
ual SUVmax, SUVpeak, and SUVmean values were reported
in this article. If these numbers are included in the analy-
sis, RCs of the SUV metrics improve by approximately
2%, yet do not influence the results significantly.
If we compare our results to those published in the orig-
inal reports, similar variability was found for SUVmax [15,
16]. Repeatability of SUVmean improved when threshold
based segmentation was applied for the Trigonis et al.
[16] cohort (RC: 29.8 vs. 21.1). In contrast, variability of
SUVmean increased in the FBP dataset compared to manual
delineation (RC: 20.6 vs. 41.9) [14]. This is also seen when
other segmentation algorithms are used for lesion delinea-
tion in this FBP reconstructed dataset and raises the issue
of appropriateness of semi-automatic segmentation in FBP
reconstructed images [21]. Unfortunately, the raw data of
this dataset were not available, so no reconstruction using
OSEM could be performed.
The repeatability of 18F–FLT SUV metrics from this
study is better than the 30% threshold suggested by PET
response criteria in solid tumors (PERCIST) for 18F–FDG
PET. The repeatability is similar to that found in a recent
prospective multi-center study (n = 10 patients, one lesion
per patient; five institutions) on 18F–FLT in gliomas (RCs
19–23%) [22]. In addition, our results are in line with
multiple other single-center repeatability studies for sev-
eral different tracers [12, 23, 24]. In general, multi-
institutional studies yield higher variability (RCs 28–
47%) [10, 11, 13]. The lower variability found in this
study might be partly explained by the fact that data were
acquired in strictly controlled single-center setting.
Moreover, no differences in uptake time between the test
and retest scans were present because static images were
generated from dynamic scans. This removed the variabil-
ity in uptake time on SUV that is typically encountered
when acquiring static images. However, a previous study
has shown that 18F–FLT tumor uptake reached equilibri-
um at 30 min post injection in NSCLC [19].
Several other studies also found poorer repeatability of
volumetric metrics compared to SUV metrics (RCs >Ta
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30%) [12, 18]. In our study, VOIs were defined using
semi-automatic segmentation to minimize user dependen-
cy. In two out of three original reports, manual delineation
was used, potentially contributing to the observed differ-
ences [14, 16]. It was expected that repeatability of volu-
metric metrics would be slightly worse in the FBP dataset
due to higher noise levels and streak artifacts. In contrast
to our expectation, PET/CT data showed a higher variabil-
ity of proliferative volume and TLU compared to PET
only data. Moreover, variability of proliferative volume
was larger in our study compared to the original report
for the PET/CT data (RCs 43.7 vs. 30.6%) [16]. This
Fig. 3 Test-and-retest SUVpeak plotted reciprocally per lesion (a) and per patient (c) with corresponding Bland–Altman plots (b and d, respectively).
Similar patterns were seen for other SUV metrics. ( Trigonis; de Langen [HNC]; de Langen [NSCLC]; Kenny)
Table 3 Mean relative differences and RCs on lesion level for several uptake metrics
Quantitative
tracer uptake
measures
Overall Kenny de Langen Trigonis
BC Overall NSCLC HNC NSCLC
Mean
difference
(%)
RC
(%)
Mean
difference
(%)
RC
(%)
Mean
difference
(%)
RC
(%)
Mean
difference
(%)
RC
(%)
Mean
difference
(%)
RC
(%)
Mean
difference
(%)
RC
(%)
SUVmax −3.14 25.54 −9.05 25.86 −3.38 19.26 −5.60 19.80 0.32 16.91 0.47 31.13
SUVpeak −2.72 23.06 −6.83 33.22 −2.56 16.42 −4.24 14.96 0.24 18.16 −0.65 24.29
SUVmean −3.32 25.16 −12.62 41.89 −1.40 14.42 −2.80 13.01 0.93 16.24 −0.72 21.12
TLU 3.70 36.38 −5.43 37.03 0.06 27.30 1.69 29.75 −2.65 23.32 12.09 41.88
Volume 5.43 35.95 −0.01 40.64 1.45 24.35 4.47 27.46 −3.59 14.47 12.84 43.68
BC breast cancer, NSCLC non-small cell lung cancer, HNC head and neck cancer, SUV standardized uptake value, TLU total lesion uptake
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discrepancy was mainly caused by low 18F–FLT uptake of
lesions in the PET/CT dataset, resulting in low tumor-to-
background ratios. As semi-automatic segmentation
methods require adequate contrast between tumor and
background radioactivity, accurate VOI definition can be
compromised. This is supported by the fact that results
significantly improve when including only lesions with
SUVmax > 4.0.
Two studies validating simplified quantitative metrics
of 18F–FLT uptake in NSCLC showed a stronger
Fig. 4 Bland–Altman plots of total lesion uptake (TLU) and proliferative volume on lesion (a and c, respectively) and patient level (b and d,
respectively). ( Trigonis; de Langen [HNC]; de Langen [NSCLC]; Kenny)
Table 4 Mean relative differences and RCs on patient level for several uptake metrics
Quantitative
tracer uptake
measures
Overall Kenny de Langen Trigonis
BC Overall NSCLC HNC NSCLC
Mean
difference
(%)
RC
(%)
Mean
difference
(%)
RC
(%)
Mean
difference
(%)
RC
(%)
Mean
difference
(%)
RC
(%)
Mean
difference
(%)
RC
(%)
Mean
difference
(%)
RC
(%)
SUVmax −3.54 20.63 −8.61 21.82 −1.82 14.92 −4.27 14.47 1.85 13.59 −1.43 28.31
SUVpeak −2.76 21.00 −5.81 31.50 −1.32 13.21 −3.74 11.07 2.31 13.82 −2.37 22.34
SUVmean −3.99 26.44 −12.14 43.26 −0.18 10.93 −1.72 9.06 2.14 12.72 −2.83 20.79
TLU 4.51 30.85 −7.10 38.73 3.52 22.83 5.75 25.26 0.18 18.79 16.58 25.22
Volume 6.67 32.81 −0.52 44.24 3.23 23.60 6.96 26.95 −2.36 12.53 20.19 27.98
BC breast cancer, NSCLC non-small cell lung cancer, HNC head and neck cancer, SUV standardized uptake value, TLU total lesion uptake
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correlation of TBR with the uptake constant Ki (estimated
from kinetic analysis) compared to SUV [19, 25]. In our
study, we found that normalizing SUV to blood pool ra-
dioactivity concentrations significantly increases variabil-
ity for 18F–FLT images reconstructed with FBP.
Moreover, TBR has been shown to be highly time depen-
dent for 18F–FLT, limiting its use in response assessment,
especially in busy clinical settings [19, 26].
It is suggested that assessment of response per patient
rather than per lesion may improve correlation with pa-
tient outcome [27]. Similar to other studies, assessing re-
peatability per patient improved RCs by reducing the non-
systematic differences between the test-and-retest scans.
To our knowledge, only one study has been performed
comparing response assessment per patient and per lesion
[28]. Here, no significant differences in performance of
the two methods were found. Yet, in this 18F–FDG study,
the same threshold of 30% to differentiate between stable
disease and progressive disease or partial response was
used for both methods [28]. We therefore propose that
future response assessment studies with 18F–FLT PET/
CT should also assess the response per patient, while tak-
ing the per-patient variability into account.
In the current study, we have used symmetric limits to
assess repeatability of quantitative 18F–FLT uptake met-
rics. Symmetrical RCs are commonly used in PET repeat-
ability literature, however recent papers have discussed
their applicability in daily clinical practice [10, 29]. In
test–retest studies, often no golden standard is available
and therefore relative differences are calculated using the
average of the two measurements. This differs from re-
sponse assessment in clinical setting where change is de-
termined relative to a single baseline value and therefore
asymmetrical RCs are suggested to be more suitable. If
we calculate asymmetric RCs at lesion level, the overall
upper (URC) and lower limits (LRC) of the RCs are:
SUVmax (URC: 29.4%; LRC: -22.7%); SUVmean (URC:
29.0%; LRC: -22.5%); SUVpeak (URC: 26.0%; LRC -
20.6%); TLU (URC: 44.6%; LRC -30.9%); and volume
(URC: 43.7%; LRC: -30.4%). These results show a slight
shift in RCs of SUV metrics compared to the symmetric
limits, however remain within 30%. On a patient level,
asymmetrical RCs improved RCs of SUV: SUVmax
(URC: 21.1%; LRC: -18.3%); SUVmean (URC: 15.3%;
LRC: -23.3%); SUVpeak (URC: 16.8%; LRC -18.8%);
TLU (URC: 34.1%; LRC -27.9%); and volume (URC:
36.3%; LRC: -28.7%).
The use of different PET scanners and the heterogene-
ity in reconstruction methods between cohorts could have
contributed to the variability in the uptake and volumetric
metrics. However, despite these limitations, repeatability
of 18F–FLT was better compared to several other standard-
ized multi-center studies that prospectively evaluated re-
peatability of 18F–FDG. In contrast to other meta-analy-
ses, we increased robustness by re-analyzing all scans and
thus minimizing variability due to data analysis and
allowing direct comparison of quantitative uptake metrics.
To date, this individual patient data meta-analysis pro-
vides the largest test–retest 18F–FLT PET cohort. These
results should ideally be confirmed in a large prospective
multi-center PET/CT study.
Conclusions
In this multi-center, individual patient data meta-analysis, we
found that repeatability of 18F–FLT tumor uptake is compara-
ble to that of 18F–FDGPET/CT. Inmulti-center studies, a 25%
and 20% difference in individual 18F–FLT SUVmetrics likely
represents a true change in tumor uptake at lesion and patient
level, respectively. In case of volumetric measurements,
higher thresholds are needed compared to SUV metrics, espe-
cially for lesions with SUVmax < 4.0 at baseline.
Fig. 5 Variability of SUVpeak (a) and proliferative volume (b) plotted
against SUVmax. The dashed horizontal lines indicate the cut-off values
used for the lesions selection strategies. ( Trigonis; de Langen [HNC];
de Langen [NSCLC]; Kenny)
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